8-K: NeuroOne and Zimmer Biomet Expand Partnership for OneRF Ablation System

NeuroOne Medical Technologies Corporation and Zimmer Biomet have expanded their distribution agreement, granting Zimmer Biomet exclusive rights to distribute NeuroOne's OneRF Ablation System in the US and certain international markets.

Summary

• NeuroOne has amended its distribution agreement with Zimmer Biomet, granting Zimmer exclusive rights to distribute the OneRF Ablation System.
• NeuroOne will receive an upfront payment of $3 million from Zimmer within 10 business days of the agreement's effective date.
• An additional $1 million payment is contingent upon achieving specific net sales milestones.
• The agreement is set to expire on September 30, 2034, but can be terminated earlier under certain conditions.
• Zimmer can terminate the agreement with 90 days' notice for any reason, while NeuroOne can terminate if Zimmer acquires a controlling interest in certain competitors.
• The OneRF Ablation System is the only FDA-cleared system in the US for both diagnostic and therapeutic use.
• The system has been used successfully in a limited launch, identifying and ablating brain tissue causing seizures.
• The technology has the potential to reduce hospital stays, surgeries, and adverse events, while enhancing patient safety through temperature control.

Sentiment

Score: 8

Explanation: The document is highly positive due to the significant upfront payment, potential milestone payment, exclusive distribution agreement, and the unique FDA clearance of the OneRF Ablation System. The partnership with Zimmer Biomet is also a strong positive. However, there are some risks associated with the agreement, such as the termination clause and the reliance on Zimmer's sales efforts.

Positives

• The expanded agreement provides NeuroOne with a significant upfront payment of $3 million.
• The potential for an additional $1 million milestone payment offers further financial upside.
• The exclusive distribution rights granted to Zimmer Biomet should lead to increased sales and market penetration.
• The OneRF Ablation System's unique FDA clearance for both diagnostic and therapeutic use provides a competitive advantage.
• The technology has demonstrated success in initial cases, suggesting strong clinical potential.
• The system's potential to reduce hospital stays and surgeries could lead to cost savings for healthcare providers.

Negatives

• The agreement can be terminated by Zimmer for any reason with 90 days' notice, creating some uncertainty for NeuroOne.
• The additional $1 million payment is contingent on achieving specific sales milestones, which may not be guaranteed.
• The agreement's long term (until 2034) could be a negative if the technology becomes obsolete or is superseded by a competitor.

Risks

• The success of the agreement depends on Zimmer Biomet's ability to effectively market and distribute the OneRF Ablation System.
• There is a risk that the sales milestones required for the additional $1 million payment may not be achieved.
• The agreement could be terminated by Zimmer with 90 days' notice, potentially disrupting NeuroOne's revenue stream.
• There is a risk that Zimmer could acquire a competitor, which would allow NeuroOne to terminate the agreement but may not be beneficial.
• The company is subject to risks related to supply chain disruptions, labor shortages, and the performance of its technology.
• The company may not be able to secure or retain coverage or adequate reimbursement for its technology.

Future Outlook

NeuroOne expects the agreement to generate meaningful revenue and drive improved profitability. They also plan to expand the indications for use of the OneRF Ablation System in the future.

Management Comments

• Dave Rosa, president and CEO of NeuroOne, stated that the agreement is a significant catalyst for the company.
• Dave Rosa expressed confidence that the partnership will allow NeuroOne to leverage Zimmer Biomet's leadership position and distribution channel.
• Brian Hatcher, President, SET and CMFT at Zimmer Biomet, said they are excited to expand the relationship with NeuroOne and look forward to launching the product.

Industry Context

This agreement reflects a trend in the medical device industry towards strategic partnerships to expand market reach and leverage specialized technologies. Zimmer Biomet, a major player in orthopedics and surgical technology, is expanding its portfolio into neurosurgery through this collaboration with NeuroOne, a company focused on innovative solutions for neurological disorders.

Comparison to Industry Standards

• The upfront payment of $3 million and potential $1 million milestone payment are within the range of similar distribution agreements in the medical device industry, but the specific terms depend on the technology and market potential.
• The exclusive distribution rights granted to Zimmer Biomet are a common practice in the industry to ensure focused sales and marketing efforts.
• The agreement's duration until 2034 is a long-term commitment, which is typical for complex medical device partnerships.
• The OneRF Ablation System's FDA clearance for both diagnostic and therapeutic use is a significant differentiator compared to other ablation technologies, which often have more limited approvals.
• Companies like Medtronic and Abbott also have a presence in the neurosurgery market, but the specific technologies and applications differ, making direct comparisons challenging.

Stakeholder Impact

• Shareholders: The agreement is expected to increase revenue and profitability, which should positively impact shareholder value.
• Employees: The agreement may lead to increased job security and potential growth opportunities.
• Customers: The agreement will provide access to the OneRF Ablation System through Zimmer Biomet's distribution network.
• Suppliers: The agreement may lead to increased demand for NeuroOne's products.
• Creditors: The agreement should improve NeuroOne's financial stability and ability to meet its obligations.

Next Steps

• Zimmer Biomet will begin distributing the OneRF Ablation System in the US and certain international markets.
• NeuroOne will work with Zimmer Biomet to integrate Product Improvements into the Products.
• The parties will negotiate in good faith regarding including additional countries to be included in the definition of Territory.
• NeuroOne will continue to develop and seek regulatory approvals for additional applications of the OneRF Ablation System.

Key Dates

Keywords

NeuroOne, Zimmer Biomet, OneRF Ablation System, distribution agreement, radiofrequency ablation, neurological disorders, epilepsy, FDA clearance, medical technology, brain surgery